Final Program

WEDNESDAY • MAY 18 397
2:20 The Role of Microbiomes in Defining Health and Disease
S.V. Lynch, PhD, San Francisco, CA
2:45 Impact of Early Life Exposures on Respiratory Disease
A. Bush, MD, London, United Kingdom
3:10 Common Origins of Chronic Respiratory and Non-Respiratory
Diseases
P.D. Sly, DSc, MBBS, MD, South Brisbane, Australia
D86
CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
CONTROVERSIES AND ADVANCES IN THE
MANAGEMENT OF VENTILATOR ASSOCIATED
PNEUMONIA
Assemblies on Microbiology, Tuberculosis and Pulmonary Infections;
Critical Care
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 3016/3018 (West Building, Level 3)
Target Audience
Clinicians working in the ICU,including doctors (attending and fellow),
respiratory therapists, nurses and trainees.
Objectives
At the conclusion of this session, the participant will be able to:
• understand new diagnostic tools for VAP;
• learn how to apply biomarkers to manage VAP;
• discuss the value and limitation of reporting VAC rates.
Ventilator associated pneumonia (VAP) remains an important illness in the ICU,
in spite of reports of “zero VAP”. In the current era, we are being asked to report
rates of ventilator associated complications(VAC), although the relation to VAP
remains unclear. At the same time, we may be able to improve management
with the application of anti-inflammatory therapies, rapid diagnostics, and
biomarker-guided therapy, and new antibiotics are being developed. This
session will examine these issues.
Chairing: M.S. Niederman, MD, New York, NY
J.E. Chastre, MD, Paris, France
1:30 Can Anti-Inflammatory Therapy Help Improve Outcomes in
VAP?
C. Feldman, MBBCh, DSc, PhD, Johannesburg, South Africa
1:50 Are New Antibiotics Going To Help Us Manage VAP in the ICU?
M.H. Kollef, MD, St. Louis, MO
2:10 Can Biomarkers Help with Antibiotic Stewardship in the ICU?
R.G. Wunderink, MD, Chicago, IL
2:30 Does Reporting Rates of VAC Improve Patient Care?
M.S. Niederman, MD, New York, NY
2:50 New Diagnostic Tests for VAP: Faster and Better?
I.S. Douglas, MD, Denver, CO
3:10 Discussion
J.E. Chastre, MD, Paris, France
D87
BASIC • CLINICAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
CLIMATE CHANGES AND RESPIRATORY
INFECTIONS
Assemblies on Environmental, Occupational and Population Health;
Clinical Problems; Microbiology, Tuberculosis and Pulmonary
Infections; Pediatrics
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 3003/3005 (West Building, Level 3)
Target Audience
Scientists and clinicians seeking novel insights on the climate change and
respiratory infections.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the latest advances in climate changes and health impact;
• learn and understand recent epidemiological changes in respiratory
infections;
• describe climate change sensitive respiratory infection and control
methods.
This symposium will integrate the current state of the art knowledge on how
climate change affects respiratory health and infections. Talks will be given by
speakers who are experts in the field. We will also highlighting the important
initiative on the impact of global climate change in respiratory diseases. The talk
will be 15 minutes followed by 5 minutes of audience questions.
Chairing: M. Mirsaeidi, MD, Miami, FL
C.S. Dela Cruz, MD, PhD, New Haven, CT
K.E. Pinkerton, PhD, Davis, CA
1:30 Climate Change, Policy and Development and Respiratory
Diseases
K. Ebi, PhD, MPH, Seattle, WA
1:50 Epidemiology Changes of Climate Sensitive Infectious
Diseases
I. Annesi-Maesano, MD, PhD, Paris, France
2:10 Adverse Outcome Pathways (AOP) for Infectious Disease
Which Are Influenced by Climate Change
K.E. Pinkerton, PhD, Davis, CA
2:30 Respiratory Fungal Infections and Climate Changes
A. Catanzaro, MD, La Jolla, CA
2:50 Nontuberculous Mycobacteria and Climate Change
J.O. Falkinham, PhD, Blacksburg, VA
3:10 Poverty, Pollution and Pneumonia: A Malawian Perspective on
Environment, Occupation and Infection
S. Gordon, MD, Blantyre, Malawi
ATS 2016 • San Francisco
WEDNESDAY AFTERNOON